BioPorto Diagnostics


DKK489.8m market cap

DKK2.8 last close

BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes products marketed for research use and The NGAL Test for the prediction of kidney failure.

Investment summary

BioPorto’s lead strategic goal is development of a test for acute kidney injury (AKI) using the biomarker NGAL. For adults using plasma NGAL, the pivotal clinical trial is being completed with the 510(k) to be submitted to the FDA in Q4 2019. The company is acquiring new data for the pediatric urine NGAL 510(k), which it hopes to submit in Q419. The NGAL test is commercially available for research purposes in the US and has been CE marked in Europe. BioPorto also sells a series of other antibodies, ELISA kits and related biologics.

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2017A 25.2 (33.1) (34.2) (20.59) N/A N/A
2018A 26.0 (42.1) (42.5) (24.34) N/A N/A
2019E 38.6 (45.9) (45.9) (23.70) N/A N/A
2020E 53.7 (48.3) (48.3) (23.74) N/A N/A
Last updated on 19/09/2019
Industry outlook

The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.

Last updated on 19/09/2019
Share price graph
Balance sheet
Forecast net cash (DKKm) 43
Forecast gearing ratio (%) N/A
Price performance
Actual 0.7 (29.3) (47.5)
Relative* (1.3) (29.5) (49.6)
52-week high/low DKK6.2/DKK2.7
*% relative to local index
Key management
Thomas Magnussen Chairman
Peter Mørch Eriksen CEO
Ole Larsen CFO
Jan Kuhlmann Andersen COO